Lyell Immunopharma (NASDAQ:LYEL) Announces Earnings Results, Beats Expectations By $0.37 EPS

Lyell Immunopharma (NASDAQ:LYEL) released its quarterly earnings results on Wednesday. The company reported ($1.69) EPS for the quarter, beating the consensus estimate of ($2.06) by $0.37, reports. The firm had revenue of $0.00 million during the quarter, compared to analyst estimates of $0.01 million. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%.

Lyell Immunopharma Stock Performance

Shares of Lyell Immunopharma stock traded up $4.63 during trading hours on Wednesday, hitting $15.40. The company’s stock had a trading volume of 1,100,241 shares, compared to its average volume of 137,513. The business has a 50 day moving average price of $10.85 and a two-hundred day moving average price of $16.77. Lyell Immunopharma has a 12-month low of $7.20 and a 12-month high of $45.00. The company has a market cap of $377.28 million, a PE ratio of -1.20 and a beta of -0.04.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on LYEL shares. Royal Bank Of Canada set a $34.00 price objective on Lyell Immunopharma in a research note on Friday, August 14th. Citigroup reissued a “market outperform” rating on shares of Lyell Immunopharma in a report on Friday, August 14th. Stifel Nicolaus started coverage on shares of Lyell Immunopharma in a research note on Thursday, August 6th. They set a “buy” rating and a $36.00 target price on the stock. HC Wainwright restated a “buy” rating on shares of Lyell Immunopharma in a research note on Friday, September 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 price target on shares of Lyell Immunopharma in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $40.86.

Lyell Immunopharma News Roundup

Here are the key news stories impacting Lyell Immunopharma this week:

• Positive Sentiment: Promising ronde-cel results: Updated data showed overall response rates of 91% in 44 patients treated in the 3L+ PiNACLE pivotal trial and 95% in 37 patients in a Phase 1/2 second-line cohort. Complete response rates were 77% and 76%, respectively; median progression-free survival had not been reached. Severe cytokine release syndrome was not observed, and severe neurotoxicity occurred in fewer than 10% of patients. The data will be presented at ASH 2026. Lyell ronde-cel data
• Positive Sentiment: Funding for development: Lyell agreed to a private placement expected to raise approximately $80 million, with proceeds intended to advance ronde-cel toward a planned Biologics License Application (BLA) submission. Lyell private placement announcement
• Neutral Sentiment: Quarterly results: The company reported a loss of $1.69 per share, narrower than analysts’ expected $2.06 loss. Revenue was effectively zero, underscoring that Lyell remains a development-stage company. Third-quarter 2026 results
• Negative Sentiment: The private placement involves issuing common shares, which could dilute existing shareholders.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell’s research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.